Currently there are no upcoming events.
CRI's Jill O'Donnell-Tormey, Ph.D., moderates the cancer immunotherapy panel on November 10, 2020, at 10:35 AM ET.
CRI's Jill O'Donnell-Tormey, Ph.D., speaks on the "Public-Private Partnerships Between Research Organizations and BioPharma to Accelerate Cancer Immunotherapies" panel on October 2, 2020, at 1 PM ET.
CRI's Jill O'Donnell-Tormey, Ph.D., speaks on the "ESMO Post-Show" webinar on September 22, 2020, at 3 PM ET.
The Focused Ultrasound Foundation (FUSF) hosts a special conversation with Jill O’Donnell-Tormey, Ph.D., CEO of the Cancer Research Institute (CRI), and Jessica Foley, Ph.D., chief scientific officer of FUSF.
CRI's Vanessa Lucey, Ph.D., MBA, speaks on the "ASCO Preview" webinar on May 27, 2020, at 3 p.m. ET.
CRI's Vanessa Lucey, Ph.D., MBA, speaks on the "Investor Panel" on May 27, 2020, at 12 p.m. CT.
CRI's Vanessa Lucey, Ph.D., MBA, speaks on the "Investing into Oncology" and "Oncology Modalities Facing Off" panels.
CRI’s Vanessa Lucey, Ph.D., MBA, speaks on the "Landscape and Evolution of the Marketplace" panel on February 27, 2020.
CRI's Vanessa Lucey, Ph.D., discusses the immuno-onocology landscape in this webinar for the biotechnology industry.
On December 4, CRI's Vanessa Hubbard-Lucey, Ph.D., MBA, is giving a talk on "Challenges and opportunities in designing immuno-oncology trials: A non-profit perspective."
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
In February 2017, Oswald became one of the first patients to receive pembrolizumab (Keytruda®) as first-line therapy for non-small cell lung cancer.
Dr. Kunle Odunsi discusses genomic testing, new treatments, and promising clinical trials in immunotherapy for ovarian cancer.